Xenon Pharmaceuticals Inc.
XENE
Rangering i aksjer
#4417
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company... Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Aksjekurs
$36.43
Markedsverdi
$3.53B
Endring (1 dag)
3.85%
Endring (1 år)
-16.13%
Land
CA
Handel Xenon Pharmaceuticals Inc. (XENE)
Kategori
Healthcare
Antall utestående aksjer for Xenon Pharmaceuticals Inc. (XENE)
Antall utestående aksjer per June 2026: 99.61M
Ifølge Xenon Pharmaceuticals Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 99.61M. Ved slutten av December 2023 hadde selskapet 66.89M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Xenon Pharmaceuticals Inc. (XENE) fra 2011 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 99.61M | 27.88% |
| 2024 | 77.89M | 16.45% |
| 2023 | 66.89M | 10.48% |
| 2022 | 60.54M | 38.77% |
| 2021 | 43.63M | 26.30% |
| 2020 | 34.54M | 33.17% |
| 2019 | 25.94M | 33.53% |
| 2018 | 19.43M | 8.01% |
| 2017 | 17.99M | 16.08% |
| 2016 | 15.49M | 8.48% |
| 2015 | 14.28M | 2.89% |
| 2014 | 13.88M | 52.78% |
| 2013 | 9.09M | 582.58% |
| 2012 | 1.33M | 0.14% |
| 2011 | 1.33M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | 154.89% |
US
|
|
| 396.00M | 297.55% |
US
|
|
| 478.91M | 380.79% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -37.57% |
NL
|
